Clearside Biomedi (CLSD)

$0.32 -0.03 (-8.61%)
Market Cap 26.06M
Revenue (ttm) 1.66M
Net Income (ttm) -34.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,069.28%
Debt to Equity Ratio 0.00
Volume 1,351,424
Avg Vol 5,568,396
Day's Range N/A - N/A
Shares Out 78.51M
Stochastic %K 52%
Beta 2.11
Analysts Sell
Price Target $4.00

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 270 3631
Fax: 678 270 4033
Address:
900 North Point Parkway, Suite 200, Alpharetta, United States
rando321456
rando321456 Jan. 20 at 1:00 AM
$CLSD Good luck everyone that's still here
1 · Reply
wishpotion
wishpotion Jan. 19 at 4:25 PM
$CLSD I would be not surprised if we see double dollar per share after tomorrow, neither if we get nothing.
2 · Reply
Qora
Qora Jan. 16 at 10:30 PM
$CLSD so, how did the auction go?
1 · Reply
jbal
jbal Jan. 16 at 8:21 PM
$CLSD barely an hour left of trading until the auction starts and this thing is dead. Any theories?
2 · Reply
Dasmin
Dasmin Jan. 16 at 2:07 AM
$CLSD Where are we at with ad hoc objections?
1 · Reply
maphere
maphere Jan. 16 at 1:49 AM
$CLSD $OCUL $EYPT $RGNX Article (Jan. 9th) by Dr. Kaiser on the TKI landscape for wAMD and mind you this doesn't include gene therapies like Regenxbio which is a one-and-done. Point being, any acquirer for any TKI company will consider the competition. A previous post I linked two ophthalmologists with one saying they would only inventory 1 TKI. TKIs work, and so does gene therapy...expecting the moon on a stock price (OCUL at this moment) would be living in a bubble...be careful with your expectations b/c BP will on any acquisition. https://www.sciencedirect.com/science/article/pii/S0022356526000017
1 · Reply
rando321456
rando321456 Jan. 15 at 12:21 PM
$RGNX $CLSD "in this particular case, new capsids that we've developed that are specifically developed for suprachoroidal. And what has that enabled us to do. We're able to get either the same amount of transgene expression with a much lower dose. Or we're able to get to the same dose and basically produce maybe 8 to 10-fold higher transgene levels."
1 · Reply
rando321456
rando321456 Jan. 14 at 12:59 AM
$CLSD $RGNX I would bet the most likely thing that happened is that Regenx is doing a bid for 8 million as a "favor" to HCR, then they do a deal with HCR to consolidate royalty liabilities and save 30-40 million on what the royalty sub owes. Hopefully we still go gangbusters at an auction though.
1 · Reply
PhatTonyC
PhatTonyC Jan. 13 at 8:20 PM
$CLSD Rando talk to us.... What are you thinking? We alll respect you!!
1 · Reply
JaumeIII
JaumeIII Jan. 13 at 5:29 PM
$CLSD what is the trading action telling us…must be some interest in the assets.
1 · Reply
Latest News on CLSD
No data available.
rando321456
rando321456 Jan. 20 at 1:00 AM
$CLSD Good luck everyone that's still here
1 · Reply
wishpotion
wishpotion Jan. 19 at 4:25 PM
$CLSD I would be not surprised if we see double dollar per share after tomorrow, neither if we get nothing.
2 · Reply
Qora
Qora Jan. 16 at 10:30 PM
$CLSD so, how did the auction go?
1 · Reply
jbal
jbal Jan. 16 at 8:21 PM
$CLSD barely an hour left of trading until the auction starts and this thing is dead. Any theories?
2 · Reply
Dasmin
Dasmin Jan. 16 at 2:07 AM
$CLSD Where are we at with ad hoc objections?
1 · Reply
maphere
maphere Jan. 16 at 1:49 AM
$CLSD $OCUL $EYPT $RGNX Article (Jan. 9th) by Dr. Kaiser on the TKI landscape for wAMD and mind you this doesn't include gene therapies like Regenxbio which is a one-and-done. Point being, any acquirer for any TKI company will consider the competition. A previous post I linked two ophthalmologists with one saying they would only inventory 1 TKI. TKIs work, and so does gene therapy...expecting the moon on a stock price (OCUL at this moment) would be living in a bubble...be careful with your expectations b/c BP will on any acquisition. https://www.sciencedirect.com/science/article/pii/S0022356526000017
1 · Reply
rando321456
rando321456 Jan. 15 at 12:21 PM
$RGNX $CLSD "in this particular case, new capsids that we've developed that are specifically developed for suprachoroidal. And what has that enabled us to do. We're able to get either the same amount of transgene expression with a much lower dose. Or we're able to get to the same dose and basically produce maybe 8 to 10-fold higher transgene levels."
1 · Reply
rando321456
rando321456 Jan. 14 at 12:59 AM
$CLSD $RGNX I would bet the most likely thing that happened is that Regenx is doing a bid for 8 million as a "favor" to HCR, then they do a deal with HCR to consolidate royalty liabilities and save 30-40 million on what the royalty sub owes. Hopefully we still go gangbusters at an auction though.
1 · Reply
PhatTonyC
PhatTonyC Jan. 13 at 8:20 PM
$CLSD Rando talk to us.... What are you thinking? We alll respect you!!
1 · Reply
JaumeIII
JaumeIII Jan. 13 at 5:29 PM
$CLSD what is the trading action telling us…must be some interest in the assets.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 13 at 5:23 PM
$CLSD don't see anything from court yet, but evidently someone knows something hold on tight
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 13 at 3:10 PM
$CLSD another substantial 4.5% holder filed yesterday he held some from double digits and quintupled his position recently under $1
0 · Reply
buyandsold
buyandsold Jan. 12 at 11:52 PM
$CLSD a cabal of Chinese opthalmologists seeks to steal great wealth from us. May the mighty US courts save us from this fate!
0 · Reply
buyandsold
buyandsold Jan. 12 at 9:24 PM
$CLSD i bid the exact amout required to pay off all debt and operate the company for 3 months during which i shall run a robust sales process and split all profits 50:50 with shareholders. How much do I need?
0 · Reply
JaumeIII
JaumeIII Jan. 12 at 8:16 PM
$CLSD some bids must of come in judging by the way it’s trading…
1 · Reply
BobMark
BobMark Jan. 12 at 8:07 PM
$CLSD This has a really bad smell. 2.7 mil. Really? Limited designated as stalking horse bidder at $2.7 million. The Ad Hoc Group of Equity Holders argues that with no funded debt and no trade debt, sale proceeds after administrative expenses should benefit equity holders. The group has challenged the sale process, arguing the company is worth $10.3 million to $20.3 million and alleging management waived a contingent $12.5 million payment from HealthCare Royalty Partners—nearly five times the stalking horse bid.
1 · Reply
JaumeIII
JaumeIII Jan. 12 at 5:20 PM
$CLSD bid deadline was today at 12:00pm…is this info available?
1 · Reply
JaumeIII
JaumeIII Jan. 12 at 5:18 PM
$CLSD
0 · Reply
rando321456
rando321456 Jan. 12 at 6:31 AM
$CLSD Hmm Regenx filing IND for SCS GA therapy
1 · Reply
Grandmasim
Grandmasim Jan. 11 at 2:55 PM
$CLSD 2.7 mill. 😂 😂 I thought, according to, you know, the experts here.......shareholders would make bank (cause that makes sense in a bankruptcy) and it would sell for 100 mill + 😂 😂
0 · Reply
Dasmin
Dasmin Jan. 10 at 8:16 PM
$CLSD Are there any scenarios possible where in which us Clearside shareholders have a good outcome?
1 · Reply
rando321456
rando321456 Jan. 9 at 9:53 PM
$CLSD HCR FROM THE TOP ROPE. We're still screwed here but atleast this will be entertaining.
1 · Reply